{
    "nctId": "NCT02702830",
    "briefTitle": "MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment",
    "officialTitle": "Understanding Exercise Intolerance After Treatment for Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Healthy Subject, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "A-VO2 differences",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with stage I-III breast cancer who began their cancer treatment 1-2 years prior to this study and have received anthracycline based chemotherapy\n* Women matched to age with our 16 post-cancer treatment participants\n\nExclusion Criteria:\n\n* Those with contraindications for MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices\n* Those with contraindications for exercise tolerance test (ETT) testing, including unstable angina or inability to exercise on a treadmill or stationary cycle\n* Those who are pregnant, claustrophobic, or unable to provide informed consent",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}